Category: 5631-96-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

A reaction vessel is charged with N-Boc 4-hydroxyl-5?-spiro-thalidomide (1 equiv.), potassium carbonate (2 equiv.) and DMF (0.5 M). 2-(2-chloroethoxy)tetrahydro-2H-pyran (1.1equiv.) is added and the reaction is heated at 110 C for 12 hours. The reaction is then cooled to ambient temperature and concentrated. The residue is taken up in water and ethyl acetate and the layers separated. The aqueous layer is extracted with ethyl acetate (2 x). The combined organic layer is washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue is used directly in the following reaction.A reaction vessel is charged with crude residue (1 equiv.), MeOH and DCM (1:1, 0.2 M). p-Toluenesulfonic acid (0.1 equiv.) is added and the reaction mixed at ambient temperature. Upon completion of the hydrolysis reaction, the volatiles are removed by rotary evaporation and the residue purified by silica gel chromatography to provide tert-butyl 7-(4-(2-hydroxyethoxy)-1,3- dioxoisoindolin-2-yl)-4,6-dioxo-5-azaspiro[2. 5]octane-5-carboxylate., 5631-96-9

As the paragraph descriping shows that 5631-96-9 is playing an increasingly important role.

Reference£º
Patent; C4 THERAPEUTICS, INC.; PHILLIPS, Andrew, J.; NASVESCHUK, Chris, G.; HENDERSON, James, A.; LIANG, Yanke; FITZGERALD, Mark, E.; MICHAEL, Ryan, E.; (790 pag.)WO2017/197056; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

EXAMPLE 1 LL- (4- [2- (2-HYDROXYETHOXY) ETHYL]-L- piperazinyl) dibenzo (b, f] [1, 4] thiazepine (base Quetiapine) To 26.2 mL of 50% aqueous solution of sodium hydroxide are added successively 5 G (14.7 mmols) de 2- (4- dibenzo [b, f] [1, 4] THIAZEPINE-11-IL-PIPERAZINE-L-IL) ethanol, 10.43 g (63.4 mmols) of 2- (2-CHLOROETHOXY)-TETRAHYDRO-2H- pyrane and 0. 49 g of tetrabutyl ammonium hydrogen sulphate. The mixture is heated at 60C for 6 hours with thorough stirring. It is cooled to 20-25C, and 45 mL de toluene and 26 mL of water are added while agitating. The phases are separated and the organic phase is washed with water (2 x 26 ML). 32 mL of water and 5 mL of 35% hydrochloric acid 35% are added and the two-phase mixture is stirred at 20-25C for 3 hours. The phases are separated and the aqueous phase is washed successively with n-butanol (10 mL) and toluene (10 ML). Then 45 ML OF toluene and 10% aqueous solution of potassium carbonate are added until the aqueous phase pH 10 is reached. The phases are separated and the aqueous phase is extracted with toluene (10 mL). The combined organic phases are evaporated to dryness under vacuum, yielding 4.80 g (85%) of the product of the title as a light yellow oil., 5631-96-9

As the paragraph descriping shows that 5631-96-9 is playing an increasingly important role.

Reference£º
Patent; LABORATORIOS VITA, S.A.; WO2005/14590; (2005); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

5631-96-9, 2-(2-Chloroethoxy)tetrahydro-2H-pyran (148 g, 0.9 mol) was added to a mixture of aqueous sodium hydroxide solution (50 %, 888 ml), tetra-n-butylammonium hydrogen sulfate (305 g, 0.90 mol) and benzene (1480 ml) and the mixture was stirred at 600 C. After approx. 6 h, there was no more conversion (there was always starting material left). Diethyl ether (2 I) and water (2 I) were added and the phases were separated. The organic layer was washed with water (1 I) and the combined aqueous phases were extracted once with diethyl ether (1 I). The combined ethereal layers were dried over magnesium sulfate, and distilled with a vigreux column, first at normal pressure (most of the solvent – diethyl ether and benzene – was distilled off), then under reduced pressure, affording three fractions containing 2-(vinyloxy)tetrahydro-2/-/-pyran: F1 : 16 g (60mbar, 65 0C, 65 % product (+ benzene, 1H NMR) F2: 56 g (60mbar, 95 0C, 90 % product (+ tributylamine, 1H NMR) F3: 19 g (60-40mbar, 95 0C, 80 % product (+ tributylamine, 1H NMR)

As the paragraph descriping shows that 5631-96-9 is playing an increasingly important role.

Reference£º
Patent; NYCOMED GMBH; WO2008/95912; (2008); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.,5631-96-9

Addition of diethanolamine to compound 3 (39.12 g, 0.24 mol)(25.23 g, 0.24 mol), Na2CO3 (31.80 g, 0.30 mol),NaI (2 g, 13.34 mmol), TBABr (0.3 g) and DMF (60 mL),It was then stirred at 140 C for 5 hours. The solvent DMF was evaporated in vacuo.Then ethyl acetate (100 mL) was added in sequence.10% NaCl aqueous solution (100 mL), stirring for 5 minutes,The aqueous phase was separated and the organic phase was washed with 100 mL of 10% aqueous NaCI.Dry anhydrous Na2SO4,After vacuum evaporation2,2′-((2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)amino)bis(ethane-1-ol) (Compound 4), pale yellow oil 50.39 g, yield 90%.It was used directly in the next synthesis without further purification.

5631-96-9 2-(2-Chloroethoxy)tetrahydro-2H-pyran 254951, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; Zhai Xuexu; (9 pag.)CN108912116; (2018); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics